Enhanced elimination of piroxicam by administration of activated charcoal or cholestyramine
- PMID: 2095346
- DOI: 10.1007/BF00316105
Enhanced elimination of piroxicam by administration of activated charcoal or cholestyramine
Abstract
This study has compared the effect of repeated administration of charcoal and cholestyramine on the elimination of piroxicam. Eight young adults were given piroxicam as a single dose of 20 mg, on 3 separate occasions. On one of the occasions charcoal was also given. On another occasion cholestyramine was also administered. The mean elimination half-life after piroxicam alone was 53.1 h. This was reduced to 40.0 h by charcoal administration and to 29.6 h after administration of cholestyramine. In the second phase of the study 7 elderly subjects received piroxicam 20 mg for 14 days on two occasions. Cholestyramine administration at the end of one of the periods reduced the mean elimination half-life of piroxicam from 52.3 h to 27.3 h.
Similar articles
-
Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.Clin Pharmacokinet. 1994 Feb;26(2):107-20. doi: 10.2165/00003088-199426020-00004. Clin Pharmacokinet. 1994. PMID: 8162655 Review.
-
The influence of cholestyramine on the elimination of tenoxicam and piroxicam.Eur J Clin Pharmacol. 1988;34(3):283-9. doi: 10.1007/BF00540957. Eur J Clin Pharmacol. 1988. PMID: 3260866 Clinical Trial.
-
Acceleration of the elimination of tenoxicam by cholestyramine in the dog.J Pharmacol Exp Ther. 1986 Jul;238(1):295-301. J Pharmacol Exp Ther. 1986. PMID: 3723402
-
The effect of cholestyramine and activated charcoal on glipizide absorption.Br J Clin Pharmacol. 1990 Nov;30(5):733-6. doi: 10.1111/j.1365-2125.1990.tb03843.x. Br J Clin Pharmacol. 1990. PMID: 2271372 Free PMC article. Clinical Trial.
-
Enhancement of xenobiotic elimination: role of intestinal excretion.Drug Metab Rev. 1984;15(5-6):1123-59. doi: 10.3109/03602538409033559. Drug Metab Rev. 1984. PMID: 6396054 Review. No abstract available.
Cited by
-
Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism.Arch Pharm Res. 2022 May;45(5):352-366. doi: 10.1007/s12272-022-01388-0. Epub 2022 May 31. Arch Pharm Res. 2022. PMID: 35639246
-
Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.Am J Cardiovasc Drugs. 2014 Apr;14(2):147-54. doi: 10.1007/s40256-013-0055-y. Am J Cardiovasc Drugs. 2014. PMID: 24277644 Free PMC article. Clinical Trial.
-
Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.Clin Pharmacokinet. 1994 Feb;26(2):107-20. doi: 10.2165/00003088-199426020-00004. Clin Pharmacokinet. 1994. PMID: 8162655 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources